Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare company whose operating businesses research, develop, manufacture and sell products focused on human health and well-being. It operates through two segments: Innovative Medicine and MedTech. Innovative Medicine develops prescription medicines across oncology,… From the company’s description.
In fiscal 2025, Johnson & Johnson reported revenue of $94.19B, up 6.0% from fiscal 2024, and net income of $26.80B. Its operating margin was 26.8%, and operations generated $24.53B in cash. Over the twelve months to Sep 27, 2026, revenue was $99.33B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Johnson & Johnson does
In the company’s own words
Johnson & Johnson (NYSE: JNJ) is a global healthcare company whose operating businesses research, develop, manufacture and sell products focused on human health and well-being. It operates through two segments: Innovative Medicine and MedTech. Innovative Medicine develops prescription medicines across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic conditions, distributing them to retailers, wholesalers, distributors, hospitals and healthcare professionals. Its products include DARZALEX, STELARA, TREMFYA and SPRAVATO. MedTech makes products for cardiovascular care, orthopaedics, surgery and vision, serving physicians, hospitals, surgical centers, eye care professionals, clinics and healthcare systems. Its offerings include Abiomed circulatory support technologies, Shockwave products, Mentor breast aesthetics and reconstruction products, ACUVUE contact lenses and TECNIS intraocular lenses. The company operates worldwide and had approximately 140,800 employees as of December 28, 2025. In October 2025, it announced plans to separate its Orthopaedics business. Its website is www.jnj.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW BRUNSWICK, NJ
- Fiscal year end
- January
- CIK
- 200406
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Johnson & Johnson — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Johnson & Johnson · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Johnson & Johnson’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Johnson & Johnson’s bonds, as funds hold them
Funds report holding 41 issues of Johnson & Johnson’s debt, $2.68B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.92%, maturing 2026 to 2060.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Johnson & Johnson and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Johnson & Johnson's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Johnson & Johnson's last four quarterly filings that the numbers alone won't show?”